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Abstract
Background: Compared to expert malaria microscopy, malaria biomarkers such as Plasmodium falciparum histidine rich
protein-2 (PfHRP-2), and PCR provide superior analytical sensitivity and specificity for quantifying malaria parasites
infections. This study reports on parasite prevalence, sick visits parasite density and species composition by different
diagnostic methods during a phase-I malaria vaccine trial.
Methods: Blood samples for microscopy, PfHRP-2 and Plasmodium lactate dehydrogenase (pLDH) ELISAs and real time
quantitative PCR (qPCR) were collected during scheduled (n = 298) or sick visits (n = 38) from 30 adults participating in a 112-
day vaccine trial. The four methods were used to assess parasite prevalence, as well as parasite density over a 42-day period
for patients with clinical episodes.
Results: During scheduled visits, qPCR (39.9%, N= 119) and PfHRP-2 ELISA (36.9%, N= 110) detected higher parasite
prevalence than pLDH ELISA (16.8%, N= 50) and all methods were more sensitive than microscopy (13.4%, N= 40). All
microscopically detected infections contained P. falciparum, as mono-infections (95%) or with P. malariae (5%). By qPCR,
102/119 infections were speciated. P. falciparum predominated either as monoinfections (71.6%), with P. malariae (8.8%), P.
ovale (4.9%) or both (3.9%). P. malariae (6.9%) and P. ovale (1.0%) also occurred as co-infections (2.9%). As expected, higher
prevalences were detected during sick visits, with prevalences of 65.8% (qPCR), 60.5% (PfHRP-2 ELISA), 21.1% (pLDH ELISA)
and 31.6% (microscopy). PfHRP-2 showed biomass build-up that climaxed (181363410 ng/mL SD) at clinical episodes.
Conclusion: PfHRP-2 ELISA and qPCR may be needed for accurately quantifying the malaria parasite burden. In addition,
qPCR improves parasite speciation, whilst PfHRP-2 ELISA is a potential predictor for clinical disease caused by P. falciparum.
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Introduction
Current malaria control goals are ambitious and include
elimination and ultimately eradication [1]. This daunting task
will require, among other things, the use of better diagnostic tools
for monitoring elimination/eradication successes through detect-
ing all malaria cases, including the huge proportions of submi-
croscopic parasitemias [2].
Microscopy, the gold standard for malaria diagnosis, has
detection limit of 10–50 parasite/mL [3,4]. Recent developments
in molecular diagnosis have pushed the detection limits for malaria
parasites to as low as 0.0004 parasite/mL using real time
quantitative PCR (qPCR) [5]. Other improvements include
quantitative detection of malaria antigens such as Plasmodium
falciparum histidine rich protein-2 (PfHRP-2) and Plasmodium lactate
dehydrogenase (pLDH) [6,7]. However, the increased sensitivity of
newer assays continue to generate discussions [8] as to whether
detected submicroscopic infections represent live or dead parasites.
While such contentions are difficult to prove, there is evidence that
submicroscopic parasitemia maintains chronic infections during
the non-transmission season in Sudan [9] and submicroscopic
infections have been shown to considerably contribute to mosquito
transmission [10]. Clearly, the diagnostic sensitivity of malaria
microscopy is suited to clinical cases when parasitemia is not
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limiting. However, elimination and eradication efforts will require
superior diagnostic platforms that can accurately reveal the true
extent of infections that are outside the diagnostic limits of malaria
microscopy.
Like microscopy, methods such as pLDH ELISA and qPCR
detect circulating parasites, and can therefore only account for
parasitemia at the time of drawing blood and not for the
sequestered parasite population. In contrast, PfHRP-2 is released
into circulation from all stages of P. falciparum parasites, and
therefore is able to account for trophozoites and schizonts that are
sequestered away from peripheral circulation [11,12]. Because it
persists in circulation, it can serve as an indicator of the magnitude
of current or recent infection.
This paper reports on the performance of microscopy, PfHRP-2
and pLDH ELISAs and qPCR during a malaria vaccine trial to 1)
detect Plasmodium events; 2) determine species composition; and 3)
show infection dynamics prior to sick visits and following
antimalarial treatment.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study, Participants and Site
The FMP-10 phase I malaria vaccine trial was conducted
between December 2008 and June 2009 at the KEMRI/Walter
Reed Project Clinical Trial Centre in the Kombewa Division of
Kisumu West District, western Kenya (Clinicaltrials.gov:
NCT00666380). This area is holo-endemic for malaria with peak
transmission occurring during the long rains (March–June) and
short rains (November–December). Cumulative malaria attack
rates for P. falciparum are about 95% during long rains and 75%
during the short rains [13]. For the study, 30 clinically healthy
malaria-experienced adults (18–50 years) were enrolled. These
individuals were randomized into two arms, 20 in the vaccine arm
and 10 controls. Blood samples (500 mL) were collected by
venipuncture, weekly for the first two weeks (days 0, 7 and 14),
on days 28, 35 and 42, then on days 56, 63, 70 and lastly on day
112. Each sample was used to detect malaria parasites by
microscopy, qPCR, PfHRP-2 and pLDH ELISAs. In addition,
samples were taken during unscheduled sick visits, and clinical
malaria episodes were treated with oral tablets of artemether/
lumefantrine (20 mg/120 mg) given as follows: 4 tablets under
direct observation at the time of initial diagnosis, 4 tablets after
8 hours and then 4 tablets twice daily (morning and evening) on
each of the following two days. The phase I clinical trial is
designed to evaluate safety and not designed or powered to
evaluate vaccine efficacy. No difference was shown in the ability of
serum to inhibit parasite growth in the vaccinated and control
groups and therefore no attempt was made to dichotomize the
study samples into vaccinated and controls.
Ethical Statement
Written informed consent was obtained from all participants
involved in the study. Scientific and ethical approvals for the study
were obtained from the Kenya Medical Research Institute
(KEMRI) Ethical Review Committee (KEMRI SSC # 1337)
and the Walter Reed Institute of Army Research (WRAIR)
Human Subject Protection Committee (WRAIR # 1417b).
Microscopy
Microscopy examination involved thick and thin blood smears
that were made as described previously [14] and stained with 3%
Giemsa for 1 hour. The smears were examined by an expert
microscopist who was blinded to the outcome of other assays and
to the clinical condition of the participants. The microscopist
counted malaria parasites against 200 white blood cells (WBCs)
from the thick film if the parasite:WBC ratio was less than #2.
Slides with parasite:WBC ratio .2 were counted against 2000 red
blood cells (RBC) on the thin smear. The parasite density was
obtained by assuming a total WBC count of 8000/mL and 4.5
million RBC/mL and at least 200 fields were examined before a
score of negative result was entered [15]. Parasite speciation was
based on morphology.
PfHRP-2 and pLDH ELISAs
PfHRP-2 and pLDH ELISAs were carried out according to
methods described previously [6,7]. Standard curves for PfHRP-2
ELISA were generated from the PfHRP-2 recombinant antigen
(kind donation from Dr Sullivan, Johns Hopkins University).
pLDH standards curves were generated from recombinant antigen
supplied in the pLDH kit (Standard Diagnostics INC, South
Korea) as a positive control. The concentration range of the pLDH
standard curve was 0.0423 to 132 ng/mL and 1.9 to 500 ng/mL
for PfHRP-2.
qPCR
For the qPCR analysis, 200 mL of EDTA blood was used to
extract nucleic acids (combined DNA and RNA) using QIAampH
MinEluteH Virus Spin kit (Qiagen Inc USA). The samples were
eluted in 100 mL elution buffer. P. falciparum 3D7 ring stage
parasites, obtained by D-sorbitol synchronization of a 3%
parasitemia laboratory culture [6], were serially diluted in
uninfected whole blood from 1500 to 0.012 parasites/mL. Dilution
series were processed in the same way as samples to generate
standards for parasite quantification by qPCR.
Quantitative PCR was carried out first for the genus Plasmodium
using primers and probes targeting the 18S ribosomal RNA gene
(18S rRNA) as described previously [5]. To obtain maximum
sensitivity, we have followed the qRT-PCR approach as in [5],
where samples with both DNA and RNA are used in reverse
transcription and subsequent real-time PCR. This genus-specific
qPCR was more sensitive (lower detection limit of 0.02 parasites/
mL) than the species-specific qPCR (lower detection limit 0.125
parasite/uL). Therefore, speciation of malaria parasites was
carried out only on samples that were positive in the genus-
specific qPCR. Both genus and species-specific qPCRs were
performed in a final volume of 10 mL that contained: 1 mL of
template nucleic acids, 5 mL of 26Qiagen Quantitect probe RT-
PCR master mix (Qiagen Inc, USA), 0.4 mM of each primer,
0.2 mM probe, 0.1 mL of Qiagen reverse transcriptase enzyme
mix, 4 mM magnesium chloride and sterile PCR grade water to
make a final volume of 10 mL. Primers and probes sequences are
listed in Table 1. Reactions were carried out on a 7300
thermocycler (Applied Biosystems). The amplification process
started with a 30 minutes reverse transcription step at 50uC to
convert RNA to cDNA. This was followed by 94uC for 10 min
and 45 cycles of 95uC for 15 s, and 60uC for 1 minute to amplify
the target cDNA and genomic DNA.
Statistical analysis
All statistical analyses were performed using SAS Version 9.1
(SAS Institute Inc Cary, N. Carolina, USA). Generalized
Plasmodium Events in a Malaria Vaccine Study
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Estimating Equations for dichotomous outcome was used to test
for differences between the four diagnostic methods in detecting
parasite prevalence, because multiple samples of each patient were
tested. pLDH and PfHRP-2 ELISA and qPCR were compared to
microscopy and between each of the methods using odds ratios. As
performance of the various techniques depends on parasite density
(e.g. submicroscopic densities can be detected by PCR, not
microscopy, whilst higher parasite densities can be accurately
detected by both methods), we have adjusted our analysis for visit
day (time since start of the study), and for the interaction between
visit day and method. General linear models were used to test
whether parasite density estimated by the 4 methods differs with
time before onset of disease, and if any time point could serve as a
predictor of clinical disease. Robust standard error was used to
adjust for repeated measurements.
Results
Prevalence of non-clinical malaria infections, measured
by the four diagnostic methods
We have compared the diagnostic value of 4 methods
(microscopy, qPCR, pLDH and PfHRP-2 ELISA) for the detection
of malaria parasites during a vaccine trial. Samples were not
dichotomized into vaccinated and control groups as the study
showed no differences between the groups. Blood samples of 30
individuals were collected during scheduled visits (n = 298) and
were evaluated for parasitemia events by the 4 different diagnostic
methods. There were significant differences between the 4
methods in detecting malaria parasite prevalence. Using data
from adjusted odds ratio, qPCR (prevalence 39.9%, confidence
interval 34.4–45.5%) and PfHRP-2 ELISA (36.9%; CI 31.4–
42.4%) performed similarly (P = 0.80) and both detected higher
prevalences compared to pLDH ELISA (16.8%; CI 12.5–21.0%)
(P,0.0001). Microscopy (13.4%; confidence interval (CI) 9.6–
17.3%) detected lower prevalences than the three other methods
(P,0.05) (Table 2; Figure 1).
Prevalence of malaria parasite species by microscopy and
qPCR
Table 3 shows the species of malaria parasites that were
identified during scheduled visits by microscopy and species-
specific qPCR during the 112-days of study. P. falciparum was the
most common malaria parasite species and was present in all
samples diagnosed positive by microscopy (N = 40), either as
mono-infections (95%, N = 38) or in combination with P. malariae
(5%, N = 2). Of the 119 samples positive by genus qPCR, 102 were
successfully amplified by the species-specific qPCRs. P. falciparum
was present in 89.2% of these infections, 71.6% (N = 73) as mono
infection, 8.8% (N = 9) with P. malariae, 4.9% (N = 5) with P. ovale
and 3.9% (N = 4) with P. malariae and P. ovale. P. malariae and P.
ovale mono-infections accounted for 6.9% (N = 7) and 1.0% (N = 1)
Table 1. Species-specific primers and probes for detecting Plasmodium parasites.
Species Type Specific Primers and Probe Sequences
P. falciparum
Forward FAL3F AGT ACA CTA TAT TCT TAT TTG AAA TTG AA
Reverse FAL3R TG CCT TAA ACT TCC TTG TGT TAG
Probe (59 FAM - 39 TAMRA) FAL3P CTC TTC TTT TAA GAA TGT ACT TGC TTG ATT
P. vivax
Forward VIV3F GCAACGCTTCTAGCTTAATCC
Reverse VIV3R CAAGCCGAAGCAAAGAAAGT
Probe (59 VIC- 39 TAMRA) VIV3P ACTTTGTGCGCATTTTGCTA
P. ovale
Forward OVA3F TAT AGC TGA ATT TGC TTA TTT TGA AG
Reverse OVA5R G CTT TAC AAT CAA ACG AAT ACA TTC
Probe (59 VIC - 39 TAMRA) OVA3P ATA CAA TTA ATG TGT CCT TTT CCC TA
P. malariae
Forward MAL4F TT TGT ATA ATT TTT TAT GCA TGG GAA TTT TG
Reverse MAL5R ATGCTGTAGTATTCAAACACAGAAAC
Probe (59 FAM- 39 TAMRA) MAL3P TGTTCAAAGCAAACAGTTAAAACA
doi:10.1371/journal.pone.0056828.t001
Figure 1. Trends in malaria prevalence by diagnostic method
among the study participants that did not develop clinical
malaria during the 112-day study. At every visit, malaria
prevalences are highest when detected by PfHRP-2 ELISA and qRT-
PCR methods and lowest when measured with microscopy and pLDH
ELISA.
doi:10.1371/journal.pone.0056828.g001
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respectively and 2.9% (N = 3) for co-infections. P. vivax was not
detected in any of the samples.
Utility of microscopy, qPCR, PfHRP-2 and pLDH ELISAs in
predicting clinical episodes
We have evaluated the utility of the 4 diagnostic methods in
quantifying malaria parasite load in patients with clinical signs
suggestive of malaria. A total of 38 acute care malaria blood
smears were requested by the clinical team over the 112 days
follow-up period for study volunteers presenting with any of the
following indicators of malaria: fever (ancillary temperature
.37.5uC), headache, backache, malaise and generalized body
pain. Blood samples from these patients were analyzed by
microscopy, PfHRP-2/pLDH ELISAs, and qPCR. Only twelve
samples (31.6%) had microscopically confirmed malaria parasites
and these patients were treated with artemether/lumefantrine as
described in the methods section. Following treatment, patients
continued to be evaluated for malaria during the scheduled visits.
As participants were clinically unwell, the probability of malaria
parasites in samples taken during these visits is higher, with
prevalences of 65.8% (qPCR), 60.5% (PfHRP-2 ELISA), 21.1%
(pLDH ELISA) and 31.6% (microscopy). Figure 2 shows the
concordance of malaria parasitemias by the four methods in the 38
individuals who reported being sick. As the levels of parasitemia
determined by micropscopy decreases, the concordance between
the different methods decreases as expected. For the 12
participants who had microscopic confirmed malaria, sensitivity
(the number of positive samples detected correctly) was 10/12
(83.3%) for both the genus-specific qPCR and PfHRP-2 ELISA
and 7/12 (58.3%) for the pLDH ELISA. Two microscopy
confirmed cases were negative for all three other diagnostic
methods, suggesting that the parasites identified by microscopy
may have been misdiagnosis, which would suggest sensitivities to
be 70% (pLDH) and 100% (qPCR and PfHRP-2 ELISA). In
addition, PfHRP-2 ELISA and qPCR detected over double the
amount of malaria cases detected by microscopy and pLDH
ELISA, most likely as these methods detect parasites densities way
beyond the detection limit of microscopy and PLDH ELISA; also
PfHRP-2 ELISA detects the antigen secreted by parasites in
previous multiplication cycles within the infection, allowing an
estimate of cumulative parasite biomass.
Figure 3 show the parasite dynamics estimated by the four
malaria diagnostic methods at days 21, 14, 7 and 0 before and
after anti-malarial treatment for the 12 individuals who had
microscopically confirmed clinical malaria. General linear model
was used to test for differences in calculated parasite densities
before onset of disease. This analysis determined if any of the days
could serve as a reliable predictor of clinical disease in a
prospective study. PfHRP-2 ELISA, but not the other methods,
shows a cumulative build-up of parasite antigen that reached a
maximum concentration (mean = 181363410 ng/mL SD) on the
day the patients reported being sick. Following anti-malarial
treatment (day 0), PfHRP-2 levels declines slowly and remains
detectable up to 21 days post treatment, whilst the other methods
cannot detect parasites or parasite products on days 7, 14 and 21
post treatment. As shown in Figure 2, there were 26 individuals
who reported sick without having malaria parasites detectable by
microscopy. However, 16 of these individuals had submicroscopic
parasitemia by PfHRP-2 and/or qPCR. Their mean PfHRP-2
levels at the day of presentation (day 0) was 260 ng/mL and
respectively 134 ng/mL, 253 ng/mL and 12 ng/mL on days 7, 14
and 21 before disease onset.
Discussion
This study provides a dataset for judging the performance of
microscopy, PfHRP-2 and pLDH ELISAs and qPCR for detecting
Plasmodium events and evaluates parasite density build-up that
culminates in malaria attributable sick visits in a cohort
participating in a 112-day malaria vaccine trial. Each of these
methods has particular attributes that appeal to different end
users. Microscopy is the gold standard for malaria diagnosis, it is
cost effective and simple to use but has a low sensitivity. When not
done well, its main drawback includes poor reproducibility,
variable sensitivity, and unacceptably high false-positive rates
[6,16–19]. The glycolytic pLDH is a secreted antigen that is found
in all Plasmodium species, and because it is short lived in blood, it is
Table 2. Pair-wise Comparison of malaria diagnostic methods using Generalized Estimating Equations (GEE).
Comparison Adjusted for visit day and interaction between method and visit
OR (95% CI) P-value
qPCR vc Microscopy 1.35 (1.20–1.52) 0.0001
qPCR vs pLDH ELISA 1.28 (1.13–1.45) 0.0001
qPCR vs PfHRP-2 ELISA 0.99 (0.90–1.09) 0.8005
PfHRP-2 ELISA vs Microscopy 1.37 (1.24–1.51) 0.0001
PfHRP-2 ELISA vs pLDH ELISA 1.30 (1.16–1.45) 0.0001
pLDH ELISA vs Microscopy 1.05 (1.00–1.11) 0.0309
doi:10.1371/journal.pone.0056828.t002
Table 3. The number and percentage of Plasmodium parasite
species detected by microscopy and qPCR.
Species Microscopy (%) qPCR (%)
Pf 38 (95) 73 (71.6)
Pf+Pm 2 (5) 9 (8.8)
Pf+Po 0 5(4.9)
Pf+Po+Pm 0 4 (3.9)
Pm 0 7 (6.9)
Po 0 1 (1.0)
Po+Pm 0 3 (2.9)
Total 40 102
Key: Pf = P. falciparum, Pm= P. malariae, Po = P. ovale.
doi:10.1371/journal.pone.0056828.t003
Plasmodium Events in a Malaria Vaccine Study
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a good indicator of current infection. However, pLDH is produced
in small quantities and this limits its sensitivity, especially for the
non P. falciparum species whose parasitemias are usually low. In
contrast, PfHRP-2 (produced by only P. falciparum) [4] has a higher
sensitivity because it is produced in large quantities and by all
stages of P. falciparum parasites [20]. For these reasons, PfHRP-2 is
the mainstay for P. falciparum rapid diagnostic tests. PfHRP-2 is
water soluble and its blood level originates from parasites in the
peripheral circulation as well as from those sequestered in
endothelial vessels and in organs such as liver, kidneys, brain
and placenta [11,12]. In addition, PfHRP-2 has a long half-life
and therefore can account for historical parasitemia. Because of
these attributes, circulating levels of PfHRP-2 reflect the total
cumulative parasite biomass [11] and could serve as an indicator
of the magnitude of recent (and potentially already cured)
infection. Molecular methods are considerably more sensitive
than most diagnostic methods, and we have used an approach that
has superior sensitivity as a result of detecting the combined RNA
and DNA of 18S rRNA gene, allowing us to detect submicroscopic
parasitemia as low as 0.02 parasite/mL [5,21]. Like microscopy
and pLDH, but unlike PfHRP-2, qPCR only detect current
parasitemias and therefore cannot account for diurnal fluctuation
or for mature trophozoite and schizont stages that are unavailable
in the peripheral circulation.
While the number of subjects taking part in the study is small
(N = 30), the numbers of samples available for analysis for the 112
days follow-up period is large (N = 298), and by using statistical
methods that account for repeated measurements, we were able to
fully benefit from this sample size. Our results show that
microscopy detects the lowest proportion of individuals with
non-clinical malaria (13.4%), followed by pLDH ELISA (16.8%)
and PfHRP-2 ELISA (36.9%) and qPCR (39.9%) (Figure 1,
Table 2). Although prevalences were higher during sick visits by all
methods tested, the sensitivity ranking of the methods did not
change. The similarity in sensitivity between microscopy and
pLDH has been shown before and is attributed to the fact that the
enzyme activity parallels the levels of peripheral parasitemia
[22,23]. The qPCR approach used in this study utilized combined
RNA and DNA to amplify the Plasmodium multicopy 18S rRNA
genes that allows detection of submicroscopic parasitemia [5]. As
shown previously in an area with predominantly P. falciparum
malaria infections [24], our study reveals comparable sensitivity
for measuring P. falciparum prevalence by PfHRP-2 detection and
prevalence of all Plasmodium species as detected by qPCR (36.9%
vs 39.9% respectively). However, some studies have reported lower
sensitivity of PfHRP-2 assays compared to PCR in pregnant
women at delivery [25,26]. As lower concordance between PCR
and PfHRP-2 assays is regularly observed [24–26], lower
performance of HRP-2 may partly be due to low parasite densities
resulting from IPTp treatment. One potential setback in the use of
PfHRP-2 as a diagnostic tool is that reported PfHRP-2 gene
deletions in parasites from South America [27] and, more recently,
from Sub-Saharan Africa [28] result in false negative results for
this test.
At the baseline of our study, pLDH ELISA and microscopy
indicated that approximately 20% of the participants had malaria
parasites (Figure 1), whilst 53% were parasitamic by qPCR and
over 70% by PfHRP-2 ELISA. This enrollment parasitemia
reflects the timing at the end of the short transmission season with
33% of infections being submicroscopic (PfHRP-2 positive and
qPCR positive) and a considerable proportion of individuals
having signs of recent but not current infection (PfHRP-2 positive
but qPCR negative). The parasite prevalence declines over time,
with more substantial declines measured by PfHRP-2 ELISA
Figure 2. Comparison of routine microscopy, pLDH/PfHRP-2 ELISA and qPCR for a group of study participants who had acute blood
smears prepared at sick visits. Each column (1–38) represents one blood sample with the corresponding microscopy, pLDH/PfHRP-2 ELISA and
qRT-PCR results, ordered by parasite density as determined by microscopy (top graph) and antigen levels (pLDH/PfHRP-2) or Ct values (qPCR). As the
levels of parasitemia decreases, the concordance between the different methods also decreases. PfHRP-2 and qPCR detect parasites densities way
beyond the detection limit of microscopy.
doi:10.1371/journal.pone.0056828.g002
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(45%) and qPCR (15%), compared to almost no decline for
microscopy and pLDH ELISA (Figure 1). Whereas we would
expect such a decline in a prospective study that proactively treats
clinical malaria every time it is reported, the disproportional
decline between the methods suggests that this decline does not
result from a reduction of clinical malaria, but from a reduction of
evidence of recent infection and a decrease of the prevalence of
submicroscopic infections over time.
Clearly, microscopy detects only the proverbial ears of the
hippo while the massive body of parasites remains sub-microscop-
ic. These data are corroborated by other studies that show that
microscopy considerably underestimates parasite rates by up to
50% [29–32]. When accounting for the potential occurrence of
mutations of the PfHRP-2 gene which may decrease sensitivity of
HRP-2 assays [27,28] and its potential lower sensitivity in some
[25,26] but not all studies [this study, 24], the highly sensitive
detection methods of PfHRP-2 ELISA and qPCR will especially
be useful for detecting malaria infections in the context of malaria
elimination and eradication, when every infected, and thus
potentially infectious, individual will need to be targeted by
control measures. One potential cause of discrepant sensitivity in
PfHRP-2 is the choice of samples used in different studies (whole
blood, plasma or serum). Our unreported data show that, malaria
infected red blood cells have up to 10 times more PfHRP-2 than in
the plasma. In the future, and as part of standardizing of these
assays, sample choice and genetic polymorphisms will need to be
evaluated.
In order to understand the infection dynamics that herald
clinical malaria, blood samples of the 12 individuals who were
treated on the basis of microscopic diagnosis were evaluated by the
different diagnostic techniques for parasite densities at 21, 14, 7
and 0 days before and after anti-malaria treatment. Of the four
tested techniques, only PfHRP-2 ELISA demonstrates a cumula-
tive parasitemia that is highest at the time patients reported to
investigators with clinical malaria and high parasite densities. For
this reason, and as reported recently [33], PfHRP-2 levels may be
useful for predicting potential clinical episodes in prospective
research studies. In the Hendriksen study [33], a plasma PfHRP-2
concentration of .1000 ng/mL was shown to represent ‘‘true’’
severe malaria and had a case fatality rate of .10%. In our study,
we are proposing that a blood PfHRP-2 concentration of
.1813 ng/mL as an indicator of a true clinical malaria. In
comparison, 26 individuals who reported sick but did not have
detectable malaria parasites by microscopy showed mean PfHRP-
2 levels at the day of presentation (day 0) that was four times lower
than those with clinical malaria. Although 16 of these individuals
had submicroscopic parasitemia by PfHRP-2 and/or qPCR
(Figure 2), these parasite densities (less than 1 parasite/200
WBC count on a thick blood film) ( =,40 parasites/mL of blood)
are unlikely to have been the cause of illness in these malaria
Figure 3. Utility of microscopy, qPCR, PfHRP-2 and pLDH ELISAs in predicting clinical episodes. Parasite dynamics before clinical malaria
attack (day 0) as measured by (A) PfHRP-2, (B) pLDH (C) Microscopy and (D) qPCR, for the 12 participants with microscopically confirmed clinical
malaria. Parasite dynamics after clinical attack are also presented for PfHRP-2 (A). Error bars represent standard error of mean of the parasitemia
values at each time point. The arrows indicate the day of treatment. Microscopy, pLDH and qPCR did not detect malaria parasites after the treatment.
doi:10.1371/journal.pone.0056828.g003
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experienced semi immune adults. Clearly, more detailed studies
are required to determine from what time point before the onset of
clinical disease PfHRP-2 increases, and how variable this period
and PfHRP-2 levels are. PfHRP-2 remained in circulation for 3
weeks post successful malaria cure. This is consistent with the
documented long half-life of PfHRP-2 [34–37]. As would be
expected for microscopy, pLDH and qPCR which measure
biomarkers that do not accumulate, parasite densities were at
undetectable levels from the first samples taken (seven days) post
treatment.
One of the main benefits of PCR and microscopy is that both
methods can be used for speciation of Plasmodium in clinical
samples. As shown in Table 3, and previous reports [38–40], P.
falciparum was the dominant malaria parasite species in our area. In
addition to underestimating prevalence, it is clear that microscopy
grossly underestimates the extent of parasite species resident in the
population [41,42]. It is known that co-infections of different
malaria parasite species lead to dominance of one species over the
other(s) [43]. The low parasite density of the suppressed parasite
species presents diagnostic challenges for the less sensitive
techniques such as microscopy. Given that malaria parasites such
as P. ovale and P. vivax form dormant hypnozoites [44] that are not
treatable by the conventional antimalarials, these minority parasite
species may disproportionally benefit from treatment-driven
elimination of the dominating parasite species, analogous to
competitive facilitation [45]. It is therefore very important to
identify submicroscopic parasitemia of these species for radical
cure to be effective. Whereas the qPCR may not be a convenient
tool for patient management in malaria endemic areas where semi
immune individuals carry low grade parasitemia of no clinical
consequence, this technique will provide a valuable addition for
monitoring submicroscopic parasitemia in the context of evaluat-
ing the newly stated goals of malaria elimination and eventually
eradication [1].
Conclusions
The study described here reports on the combined performance
of four diagnostic methods of malaria for monitoring parasite
prevalence in a longitudinal study set up. The findings illustrate
scores of submicroscopic Plasmodium infections that go undetected
by microscopy. As previously suggested [29–32], malaria micros-
copy is therefore inaccurate as a tool for monitoring malaria
prevalence, especially when low parasite densities are common. As
the world aims to move towards the stated agenda of malaria
elimination and subsequent eradication, malaria detection will
shift from monitoring clinical disease to screening for asymptom-
atic carriers. Diagnostic methods such PfHRP-2 ELISA and qPCR
with the analytical sensitivity documented in this and other studies
[5 and 6) will be needed for accurate evaluation of the stated goals.
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